Otros idiomas JW (Cayman) Therapeutics Co. Ltd

Acciones

2126

KYG5210T1040

Mercado cerrado - Hong Kong S.E. Otros sitios de cotización 10:08:22 10/05/2024			Varia. Cinco días.	Varia. 1 de enero.
2,43 ^HKD	+29,95 %		+27,89 %	+7,52 %

20/03	JW (Caimán) Therapeutics reduce sus pérdidas en el ejercicio fiscal 2023	MT
20/03	JW (Caimán) Therapeutics Co. Ltd informa de los resultados del ejercicio finalizado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023	20/03
JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
China Regulator Accepts JK Therapeutics' Supplemental License Application for Lymphoma Therapy	05/01
JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva in Patients with Relapsed or Refractory Mantle Cell Lymphoma	04/01
JW (Cayman) Therapeutics Signs Collaboration Deal for Development of Autoimmune Disease Treatment	03/01
JW Therapeutics Announces Exclusive Collaboration with 2Seventy Bio for Autoimmune Disease Car-T Therapy	02/01
JW Therapeutics CFO Resigns	18/12
JW Therapeutics Co. Ltd Announces Resignation of Xin Fu as Chief Financial Officer	15/12
JW (Cayman) Therapeutics to Expand Strategic Alliance with Cell and Gene Therapy Firm	13/09/23
2Seventy Bio, Inc. and Jw Therapeutics Announce Intent to Expand Strategic Partnership to Accelerate the Research and Development of T Cell-Based Immunotherapies and Autoimmune Therapies	12/09/23
JW Therapeutics Co. Ltd Announces Board Changes	30/08/23
JW Therapeutics' H1 Attributable Loss Narrows on Higher Revenue	29/08/23
JW Therapeutics Co. Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	29/08/23
JW (Cayman) Therapeutics to Buy Viral Vector from Substantial Shareholder	22/05/23
China Gives Investigational New Drug Clearance to JW Therapeutics' Anti-Lupus Injection; Shares Rise 7%	11/04/23
JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus	10/04/23
JW Therapeutics' 2022 Loss Widens	30/03/23
JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	29/03/23
JW (Cayman) Therapeutics Initiates Clinical Study for B-Cell Lymphoma Injection	08/03/23
JW Therapeutics Co. Ltd. Announces Initiation of Clinical Study of Carteyva® in First-Line Treatment in Patients with High-Risk Large B-Cell Lymphoma	08/03/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas JW (Cayman) Therapeutics Co. Ltd

Acciones

2126

KYG5210T1040

Otros idiomas

Filtros